Deborah Whatley, APRN
Psychiatric/Mental Health · Lexington, SCNPI 1184110900
Payments from drug & device makers
Across 829 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$2K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$1K
- plus $3K from 15 others
What the payments were for
- Consulting fees$3753%
- Speaking & faculty fees$1881%
- Food & beverage$12,20394%
- Education$1541%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 115 | $2,133 |
| AbbVie | 185 | $1,999 |
| Teva Pharmaceuticals USA, Inc. | 178 | $1,802 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 79 | $1,435 |
| Otsuka America Pharmaceutical, Inc. | 64 | $1,300 |
| Johnson & Johnson | 61 | $1,298 |
| Alkermes, Inc. | 43 | $959 |
| E.r. Squibb & Sons, L.L.C. | 22 | $528 |
| Indivior Inc. | 30 | $422 |
| Vanda Pharmaceuticals Inc. | 16 | $263 |
| Supernus Pharmaceuticals, Inc. | 9 | $175 |
| Idorsia Pharmaceuticals US Inc | 2 | $131 |
| Axsome Therapeutics, Inc. | 6 | $124 |
| Lundbeck LLC | 6 | $119 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $51 |
| Noven Therapeutics, LLC | 3 | $41 |
| Eisai Inc. | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $37 |
| Merck | 2 | $29 |
| Tris Pharma Inc | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,919 in reported general payments places this provider in the 95th percentile of 354 psychiatric/mental health providers in South Carolina.
See all psychiatric/mental health providers in South Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 43 | $362,870 |
| Invega SustennaPaliperidone Palmitate | 92 | $257,052 |
| VraylarCariprazine Hcl | 166 | $244,212 |
| AustedoDeutetrabenazine | 22 | $208,243 |
| Invega TrinzaPaliperidone Palmitate | 17 | $147,016 |
| PerserisRisperidone | 28 | $74,743 |
| AristadaAripiprazole Lauroxil | 16 | $50,327 |
| Abilify MaintenaAripiprazole | 12 | $34,843 |
| Clozapine | 148 | $9,175 |
| Aripiprazole | 75 | $8,832 |
| TrintellixVortioxetine Hydrobromide | 11 | $7,483 |
| SaphrisAsenapine Maleate | 12 | $6,851 |
| Quetiapine Fumarate | 217 | $2,448 |
| Divalproex Sodium | 55 | $2,238 |
| Paliperidone ErPaliperidone | 21 | $2,213 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $1,298 | $404,069109 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $2,133 | $362,87043 claims |
| AbbVieVraylar, Saphris | $1,999 | $251,062178 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $1,802 | $208,24322 claims |
| Indivior Inc.Perseris | $422 | $74,74328 claims |
| Alkermes, Inc.Aristada | $959 | $50,32716 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,300 | $34,84312 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $37 | $7,48311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 354 psychiatric/mental health providers in South Carolina.
Other psychiatric/mental health in Lexington
- Lysa DelgrossoLexington$9K
- Holly LewisLexington$4K
- Steven KrozerGreenville$139K
- Luron FlemingGreenville$61K
- Cerrissa HugieCharleston$54K
- Karen FulwoodMyrtle Beach$30K
- Taylor CrewsIsle Of Palms$28K
- Lauren DyerGreenville$16K
- Melissa BrownGreenville$16K
- Mary McManusNorth Myrtle Beach$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.